CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
2
1
1
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Rd1302 Cell Infusion
Research Leaders
7 sponsors active, led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 2 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (2)
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
Research Network
Common Treatments
- Rd1302 Cell Infusion1
- T Cell Injection Targeting Cd7 Chimeric Antigen Receptor1
Active Sponsors
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
- The First Affiliated Hospital of Zhengzhou University1
- Chinese Academy of Medical Sciences1
- First Affiliated Hospital of Zhejiang University1
- Nanjing Bioheng Biotech Co., Ltd.1
Top Investigators
Peking University People's Hospital
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chinese Academy of Medical Sciences
First Affiliated Hospital of Zhejiang University
The First Affiliated Hospital of Zhengzhou University
Related Conditions
- Nk Tcell Lymphoma1
- Cart Therapy1